checkAd

    DGAP-News  181  0 Kommentare Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities - Seite 4


    24.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    Language: English
    Company: Formycon AG
    Fraunhoferstraße 15
    82152 Planegg-Martinsried
    Germany
    Phone: 089 864667 100
    Fax: 089 864667 110
    Internet: www.formycon.com
    ISIN: DE000A1EWVY8
    WKN: A1EWVY
    Indices: Scale 30
    Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1170518

     
    End of News DGAP News Service

    Lesen Sie auch

    1170518  24.02.2021 

    fncls.ssp?fn=show_t_gif&application_id=1170518&application_name=news&site_id=wallstreet
    Seite 4 von 4



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities - Seite 4 DGAP-News: Formycon AG / Key word(s): Miscellaneous Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities 24.02.2021 / 07:00 The issuer is solely responsible …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer